Federal grants to Fannin Partners LLC
Fannin Partners LLC in Houston, Texas received $5.6 million in federal grants from fiscal 2021 to 2025, across 8 awards. Its largest program was Cancer Treatment Research, with $2.1 million. In fiscal 2025 it was awarded $1.3 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$5.6 million
- Awards8
- Awarded in FY 2025$1.3 million
- Largest award$2.1 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 2 | $1.1 million |
| FY 2022 | 3 | $2.3 million |
| FY 2023 | 2 | $284,287 |
| FY 2024 | 2 | $566,443 |
| FY 2025 | 2 | $1.3 million |
Programs that fund Fannin Partners LLC
| Program | Awards | Amount |
|---|---|---|
| Cancer Treatment Research | 1 | $2.1 million |
| Research Infrastructure Programs | 1 | $2.0 million |
| Drug Use and Addiction Research Programs | 1 | $320,000 |
| Vision Research | 1 | $300,016 |
| Biomedical Research and Research Training | 1 | $299,921 |
| Military Medical Research and Development | 1 | $246,443 |
| Food and Drug Administration Research | 1 | $199,972 |
| Child Health and Human Development Extramural Research | 1 | $139,727 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 7 | $5.3 million |
| Department of Defense | 1 | $246,443 |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Early clinical development of a novel IL-7R antibody for treating children with relapsed t-cell leukemia - project summary treatment of patients with relapsed t-cell acute lymphoblastic leukemia (t-all) remains a major unmet medical need, with a five-year survival of only 21-39% in children and 20% | Cancer Treatment Research | March 30, 2022 | $2.1 million |
| Aptamer therapeutic for safe and low-cost treatment of snake bite envenomation - snake bite envenomation is a significant problem in the us and worldwide that can result in substantial morbidity and even death. Snake venom contains a complex mixture of toxins including neurotoxins and myotoxins, as | Research Infrastructure Programs | June 23, 2021 | $2.0 million |
| Investigation of a novel PDE4B inhibitor for stimulant use disorder - project summary fannin partners is developing a drug, 11H, for the management of stimulant use disorders (STUD), an area of major unmet medical need. Our key innovation is selective inhibition of a key inflammatory pathway in the | Drug Use and Addiction Research Programs | April 19, 2024 | $320,000 |
| Developing SCG3 raptamers as a novel targeted therapy for wet amd - age-related macular degeneration (AMD) is a prevalent degenerative condition affecting the macula, particularly among individuals over 65 years old, with its global burden expected to reach 288 million cases by 2040. Neovascular amd | Vision Research | September 11, 2025 | $300,016 |
| Expediting the biomarker discovery process through a novel bead-based aptamer capture platform - project summary: fannin innovation studio is developing a new discovery proteomics platform called the unified process that identifies potential biomarkers in biological samples and simultaneously select | Biomedical Research and Research Training | August 15, 2022 | $299,921 |
| Development of a novel selective PDE4 inhibitor for the treatment of multiple sclerosis | Military Medical Research and Development | July 25, 2024 | $246,443 |
| Bedside right-heart catheterization for early diagnosis and more effective management of patients with heart failure and primary pulmonary hypertension - project summary over 3 million people are diagnosed with heart failure with preserved ejection fraction (HFPEF) annually in the us. Despite its hi | Food and Drug Administration Research | September 29, 2023 | $199,972 |
| Uterine wall-membrane anchor device for the prevention of preterm premature rupture of the membranes following fetoscopic surgery | Child Health and Human Development Extramural Research | February 28, 2021 | $139,727 |
Questions people ask
How much federal grant money does Fannin Partners LLC get?
$5.6 million in 8 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Fannin Partners LLC the most?
The Department of Health and Human Services, with $5.3 million in 7 awards. The Department of Defense follow.
What is Fannin Partners LLC's largest federal grant?
$2.1 million under Cancer Treatment Research, with its first action in the period on March 30, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Fannin Partners LLC?
Its largest are Cancer Treatment Research, Research Infrastructure Programs and Drug Use and Addiction Research Programs.
Other grant recipients in Houston
- Baylor College of Medicine
- The Univeristy of Texas M.D. Anderson Cancer Center
- Metropolitan Transit Authority of Harris County
- University of Texas Health Science Center at Houston
- Harris County
- University of Houston System
- William Marsh Rice University
- City of Houston
Largest federal grant recipients in Texas · Federal grants in Texas